Y-Prime LLC
, an enterprise consulting and eClinical products company, has established a systems integration partnership with
Veeva Systems
, a company in cloud-based business solutions for the global life sciences industry.
Together, the companies aim to provide global life sciences organizations with the tools to establish a content management solution as well as the ability to facilitate a smooth migration of legacy ECM platforms, such as Documentum and FirstDoc, to Veeva Vault in the cloud.
"Y-Prime has deep domain expertise in document management solutions..." explains Dan Glass, vice president of Enterprise Content Management at Y-Prime. "As global life sciences companies seek to migrate from expensive, legacy systems such as Documentum, our partnership with Veeva offers a path that integrates the change management, technical implementation and training expertise that will ensure a successful transition to the Vault Enterprise applications. For those companies that have not invested in ECM as yet," Dan continues, "our deep domain experience will play a significant role in helping companies to develop a strategy to fully realize the benefits of Vault Enterprise."
Veeva Systems recently announced Vault Enterprise, the first cloud-based suite of content management applications developed specifically for the global life sciences industry. Spanning every major part of a life sciences company - from R&D to clinical trials to manufacturing, medical communications and marketing - Vault Enterprise aims to give the pharmaceutical, biotechnology and medical products companies the ability to deploy a single technology solution globally. The results are faster implementations, dramatic cost savings and reduced regulatory risk.
"Y-Prime's knowledge of the legacy environments operating in this industry makes them well-suited to assist our customers in their moves to the cloud," says Jennifer Goldsmith, vice president of strategy, Veeva Vault at Veeva Systems. "Working together, we will help our clients reduce time to market and ensure regulatory compliance through the implementations of Vault Enterprise."
Global life sciences companies engage Y-Prime's ECM and eCTD practice team to develop transformative strategies combined with technical expertise in cloud transformation, externalization and harmonization as well as business process consulting. Y-Prime also provides eClinical systems consulting as well as a suite of cloud-based eClinical solutions; Prime IWRS, Prime eMVR, Prime ePRO and Prime Publisher.
Please visit Veeva (Booth 201) and Y-Prime (Booth 311) at the Drug Industry Association's EDM and ERS/eCTD Conference October 8-11 at the Hilton Baltimore.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.